BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

BNP Paribas Financial Markets reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 82.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,738 shares of the biotechnology company’s stock after selling 13,093 shares during the quarter. BNP Paribas Financial Markets’ holdings in Arcturus Therapeutics were worth $46,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in Arcturus Therapeutics by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after acquiring an additional 742 shares during the period. Ameriprise Financial Inc. grew its position in shares of Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 883 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Arcturus Therapeutics by 7.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 1,279 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its position in shares of Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 2,036 shares in the last quarter. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Trading Up 1.5%

NASDAQ ARCT opened at $13.00 on Wednesday. The firm has a market capitalization of $352.57 million, a price-to-earnings ratio of -5.86 and a beta of 2.36. The firm’s 50 day simple moving average is $11.33 and its 200 day simple moving average is $14.68. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. On average, equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Citigroup restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Scotiabank assumed coverage on shares of Arcturus Therapeutics in a research report on Wednesday, May 28th. They set a “sector outperform” rating and a $32.00 target price on the stock. Finally, Wells Fargo & Company decreased their target price on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Buy” and a consensus price target of $53.50.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.